UNSPSC 51312001: Carebastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C32H37NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75DLN707DO, chemically known as benzeneacetic acid, 4-(4-(4-(diphenylmethoxy)-1-piperidinyl)-1-oxobutyl)-alpha,alpha-dimethyl- but generally known as carebastine, which bears US NIH Compound Identifier 65820. European Medicines Agency schedules Carebastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06623MIG.

UNSPSC 51312001 Carebastine is a Commodity code, but the recent state and local procurement activity tagged under it does not align with carebastine (an antihistamine) or any single pharmaceutical active ingredient. Instead, the code appears to capture a mix of pharmaceutical procurement activities spanning naloxone kits, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local governments are using this code designation for health department acquisitions of emergency opioid-reversal supplies, state health and human services commission initiatives to restructure pharmacy benefit contracting, and cooperative purchasing alliances sourcing generic drugs and OTC items for statewide distribution networks. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing coalitions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes participating jurisdictions in Oregon and multiple other states). The mix suggests this code serves as a catch-all for pharmaceutical procurement that does not fit narrower active-ingredient or product-category codes.

Activity is concentrated in Florida, Texas, and Minnesota, though MMCAP's cooperative structure spans multiple states. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and potential FEMA funding. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) as a preliminary market-intelligence solicitation to inform design of a direct-to-manufacturer pharmacy program, indicating early-stage state-level interest in restructuring pharmaceutical sourcing. MMCAP issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract effectiveness July 1, 2026, and evaluations weighted 75 percent on price competitiveness. The code's loose mapping to actual purchases and the diversity of pharmaceutical procurement types across recent opportunities signal that business development professionals should confirm specific product and service scope before pursuing opportunities tagged to this code.